

Amendments to the Claims

This listing of claims replaces all prior versions, and listings, of claims in the above-identified application:

1. (Currently Amended) An isolated monoclonal antibody that specifically binds to an amino acid sequence depicted at SEQ ID NO:1[[,]] or an immunogenic fragment thereof.
- 2-4. (Canceled)
5. (Original) The antibody of claim 1 wherein the antibody is covalently attached to a compound.
6. (Original) The antibody of claim 5 wherein the compound is a chemotherapeutic agent.
7. (Original) The antibody of claim 5 wherein the compound is a detectable marker.
8. (Original) The antibody of claim 7 wherein the detectable marker is a fluorescent marker.
9. (Original) The antibody of claim 1 wherein the antibody specifically binds to an amino acid sequence depicted at amino acids 13-27 of SEQ ID NO:1.
10. (Original) A composition comprising an antibody of claim 1.
11. (Original) The composition of claim 10 further comprising a pharmaceutically acceptable carrier.

12. (Currently Amended) A method for making an antibody comprising administering to an animal a polypeptide comprising an amino acid sequence depicted at amino acids 13-27 of SEQ ID NO:1[[,]] or an immunogenic fragment thereof, and isolating the antibody from the animal, wherein the isolated antibody specifically binds to the amino acid sequence.

13. (Previously Presented) The method of claim 12 wherein the polypeptide or immunogenic fragment thereof is covalently attached to a carrier polypeptide.

14. (Currently Amended) A method for making an antibody comprising:
administering to an animal a polypeptide comprising an amino acid sequence depicted at amino acids 13-27 of SEQ ID NO:1[[,]] or an immunogenic fragment thereof;
obtaining from the animal a cell that produces the antibody;
making a monoclonal antibody-producing hybridoma using the cell; and
isolating a monoclonal antibody from the monoclonal antibody-producing hybridoma,
wherein the isolated monoclonal antibody specifically binds to the amino acid sequence.

15. (Original) A polyclonal antibody produced by a method of claim 12.

16. (Original) A monoclonal antibody produced by a method of claim 14.

17-28. (Canceled)

29. (Currently Amended) A method for detecting a polypeptide comprising:
providing a cell;
analyzing the cell for a polypeptide, wherein the polypeptide has a molecular weight of 36 kDa as measured following electrophoresis on a sodium dodecyl sulfate (SDS)-polyacrylamide

gel, and is recognized by an isolated antibody that specifically binds to a polypeptide comprising the amino acid sequence depicted in SEQ ID NO:1; and

determining whether the cell expresses the polypeptide;

wherein analyzing the cell for a polypeptide comprises contacting the cell with an antibody that specifically binds to the amino acid sequence depicted at SEQ ID NO:1 or an immunogenic fragment thereof, and detecting the bound antibody.

30. (Original) The method of claim 29 wherein the cell is *ex vivo*.
31. (Original) The method of claim 30 wherein the cell is a tumor cell.
32. (Original) The method of claim 31 wherein the tumor is a breast tumor.
33. (Original) The method of claim 29 wherein the cell is *in vivo*.
34. (Currently Amended) The method of claim 33 ~~30~~ wherein the cell is a tumor cell.
35. (Currently Amended) The method of claim 34 ~~31~~ wherein the tumor is a breast tumor.
36. (Canceled)
37. (Currently Amended) The method of claim 29 ~~36~~ wherein the antibody is covalently attached to a detectable marker.
38. (Previously Presented) The method of claim 37 wherein the detectable marker is a fluorescent marker.

39-51. (Canceled)

52. (Currently Amended) A kit comprising the isolated monoclonal antibody of claim 1 an isolated antibody that specifically binds to an amino acid sequence depicted at SEQ ID NO:1, or an immunogenic fragment thereof, and a packaging material.

53. (New) The isolated monoclonal antibody of claim 1, wherein the monoclonal antibody comprises a humanized monoclonal antibody.

54. (New) The antibody of claim 53 wherein the antibody is covalently attached to a compound.

55. (New) The antibody of claim 54 wherein the compound is a chemotherapeutic agent.

56. (New) The antibody of claim 54 wherein the compound is a detectable marker.

57. (New) The antibody of claim 56 wherein the detectable marker is a fluorescent marker.

58. (New) The antibody of claim 53 wherein the antibody specifically binds to an amino acid sequence depicted at amino acids 13-27 of SEQ ID NO:1.

59. (New) A composition comprising an antibody of claim 53.

60. (New) The composition of claim 59 further comprising a pharmaceutically acceptable carrier.

61. (New) The method of claim 29 wherein the isolated antibody comprises a monoclonal antibody.
62. (New) The method of claim 61 wherein the monoclonal antibody comprises a humanized monoclonal antibody.
63. (New) The kit of claim 52 wherein the monoclonal antibody comprises a humanized monoclonal antibody.